Skip to content

UroGen Pharma URGN Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

Pfizer logo
PfizerPFE
Johnson & Johnson logo
Johnson & JohnsonJNJ
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%
Enterprise value$1.81B+80.9%
P/S12.3×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's accrued manufacturing costs?
UroGen Pharma (URGN) reported accrued manufacturing costs of $9.84M in Q1 2026.
How has UroGen Pharma's accrued manufacturing costs changed year-over-year?
UroGen Pharma's accrued manufacturing costs increased by 41.2% year-over-year, from $6.97M to $9.84M.
What is the long-term trend for UroGen Pharma's accrued manufacturing costs?
Over 5 years (2020 to 2025), UroGen Pharma's accrued manufacturing costs has grown at a 7.2% compound annual growth rate (CAGR), from $9.55M to $13.52M.